A systematic review of evidence for the appropriateness of neonatal screening programmes for inborn errors of metabolism

Journal of Public Health (United Kingdom)

Volumn 20, Issue 3, 1998, Pages 331-343

  Thomason, Margaret J ^a   Lord, Joanne ^a   Bain, Murray D ^a   Chalmers, Ronald A ^a   Littlejohns, Peter ^a   Addison, G Michael ^b   Wilcox, A Hervey ^c   Seymour, Carol A ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b ROYAL MANCHESTER CHILDREN S HOSPITAL   (United Kingdom)

^c ST HELIER HOSPITAL   (United Kingdom)

Author keywords

inborn errors of metabolism; literature review; mass spectrometry; neonatal screening

Indexed keywords

ACYL COENZYME A DEHYDROGENASE; BIOTINIDASE; GLUTARIC ACID;

ARTICLE; BLOOD EXAMINATION; CONGENITAL ADRENAL HYPERPLASIA; COST EFFECTIVENESS ANALYSIS; HUMAN; INBORN ERROR OF METABOLISM; LITERATURE; NEWBORN; NEWBORN SCREENING; NUTRITIONAL DEFICIENCY; PHENYLKETONURIA; PRIORITY JOURNAL; TECHNOLOGY; VITAMIN DEFICIENCY;

EVIDENCE-BASED MEDICINE; HUMANS; INFANT, NEWBORN; LONDON; METABOLISM, INBORN ERRORS; NEONATAL SCREENING; PROGRAM EVALUATION; TECHNOLOGY ASSESSMENT, BIOMEDICAL;

EID: 0031692066     PISSN: 17413842     EISSN: 17413850     Source Type: Journal    
DOI: 10.1093/oxfordjournals.pubmed.a024777     Document Type: Article

References (65)

1. Smith I, Cook B, Beasley M. Review of neonatal screening programme for phenylketonuria. BrMedJ 1991; 303: 333-335.
2. Novello AC. Inherited metabolic diseases: collaborating for the health of all children. Biochem Med Metab Biol 1993; 49: 277-284.
3. Streetly A, Grant C, Pollitt RJ, Addison GM. Survey of scope of neonatal screening in the United Kingdom. Br Med J 1995; 311: 726.
4. Tappin DM, Girdwood RWA, Kennedy R, et al. An audit of infants 'unscreened' by the neonatal screening system in Scotland during 1991. Screening 1995; 3: 201-207.
5. Clayton EW. Issues in state newborn screening programs. Pediatrics 1992; 90: 641-646.
6. Wilson JM, Jungner G. Principles and practice of screening for disease. Public Health Papers, 34. Geneva: World Health Organization, 1968: 26-39.
7. Woolf SH, Battista RN, Anderson GM, Logan AG, Wang E. Assessing the clinical effectiveness of preventive maneuvers: analytic principles and systematic methods in reviewing evidence and developing clinical practice recommendations. A report by the Canadian Task Force on the Periodic Health Examination. J Clin Epidemiol 1990; 43: 891-905.
8. Canadian Task Force on the Periodic Health Examination. The Periodic Health Examination. Can Med Assoc J 1979; 121: 1193-1254.
9. Seddon HR, Green A, Gray RG, Leonard JV, Pollitt RJ. Regional variations in medium-chain acyl-CoA dehydrogenase deficiency. Lancet 1995; 345: 135-136.
10. WarnerRogers J, Waisbren SE, Levy HL. Cognitive function in early treated biotinidase deficiency: follow-up of children detected by newborn screening. Screening 1995; 4: 125-130.
11. Pang S, Clark A. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency: newborn screening and its relationship to the diagnosis and treatment of the disorder. Screening 1993; 2: 105-139.
12. Nordenstrom A, Thilen A, Hagenfeldt L, et al. Benefits of screening for congenital adrenal hyperplasia in Sweden. In: Levy HL, Hermos RJ, Grady GF, eds. Third International Meeting of the Society for Neonatal Screening. Boston, MA: Third International Society for Neonatal Screening, 1996: 211-212.
13. Honeyman MM, Green A, Holton JB, Leonard JV. Galactosaemia: results of the British Paediatric Surveillance Unit Study, 1988-90. Arch Dis Child 1993; 69: 339-341.
14. Makowski GS, Aslanzadeh J, Hopfer SM. In situ PCR amplification of Guthrie card DNA to detect cystic fibrosis mutations. Clin Chem 1995; 41: 477-479.
15. Ostrup J, Jones M, Martinmaki A. A concept for full automation of immunoassays performed in newborn screening laboratories. In: Levy HL, Hermos RJ, Grady GF, eds. Third Meeting of the International Society for Neonatal Screening. Boston, MA: Third International Society for Neonatal Screening, 1996: 171-172.
16. Chace DH, Millington DS, Terada N, et al. Rapid diagnosis of phenylketonuria by quantitative analysis for phenylala-nine and tyrosine in neonatal blood spots by tandem mass spectrometry. Clin Chem 1993; 39: 66-71.
17. Aim J, Larsson A, Rosenqvist U. Health economic analysis of the Swedish neonatal metabolic screening programme. A method of optimizing routines. Med Decision Making 1982; 2: 33-45.
18. Anonymous. Massachusetts Department of Public Health. Cost-benefit analysis of newborn screening for metabolic disorders. N Engl J Med 1974; 291: 1414-1416.
19. Barden HS, Kessel R, Schuett VE. The costs and benefits of screening for PKU in Wisconsin. Social Biol 1984; 31: 1-17.
20. Bush JW, Chen MM, Patrick DL. Health status index in cost effectiveness: analysis of PKU program. In: Berg RL, ed. Health Status Indexes. New York: Hospital and Educational Trust, 1973: 172-209.
21. Cockburn F, Clark BJ, Byrne A, et al. Maternal phenylketonuria-diet dangers and dilemmas. Int Pediatr 1992; 7(1): 67-74.
22. Dagenais DL, Courville L, Dagenais MG. A cost-benefit analysis of the Quebec Network of Genetic Medicine. Social SciMed 1985; 20: 601-607.
23. Dhondt JL, Farriaux JP, Sailly JC, Lebrun T. Economic evaluation of cost-benefit ratio of neonatal screening procedure for phenylketonuria and hypothyroidism. J Inherited Metab Dis 1991; 14: 633-639.
24. Dunkel G, Scriver CR, Clow CL, et al. Prospective ascertainment of complete and partial serum biotinidase deficiency in the newborn. J Inherited Metab Dis 1989; 12: 131-138.
25. Hisashige A. Health economic analysis of the neonatal screening program in Japan. Int J Technol Assessment Hlth Care 1994; 10: 382-391.
26. Holtzman NA. Pitfalls of newborn screening (with special attention to hypothyroidism): when will we ever learn? Birth Defects: Original Article Series 1983; 19: 111-120.
27. Komrower GM, Sardharwalla IB, Fowler B, Bridge C. The Manchester regional screening programme: a 10-year exercise in patient and family care. BrMedJ 1979; 2: 635-638.
28. Sprinkle RH, Hynes DM, Konrad TR. Is universal neonatal hemoglobinopathy screening cost-effectiveness? Arch Pediatr Adolescent Med 1994; 148: 461-469.
29. Thomason MJ, Lord J, Bain MD, et al. Newborn screening for inborn errors of metabolism: a systematic review. Health Technol Assess 1997; 1(11).
30. Cappuccio FP, Hickman M, Barker M. Neonatal screening. Performance is hard to monitor. Br Med J 1996; 312: 182.
31. Scriver CR, Kaufman S, Eisensmith RC, Woo SLC. The hyperphenylalaninemias. In: Scriber CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Bases of Inherited Disease, 7th edn. New York: McGraw-Hill, 1995: 1015-1075.
32. Bibunstruct
33. Smith I, Brenton DP. Hyperphenylalaninaemias. In Fernandes J, Saudubray J-M, van der Berghe G, eds. Inborn Metabolic Diseases. Berlin: Springer-Verlag, 1995: 147-160.
34. Chuang DT, Shih VE. Disorders of branched chain amino acid and keto acid metabolism. In: ScriverCR, Beaudet AL, Sly WS, Valle D, eds. The Molecular and Metabolic Bases of Inherited Disease, New York: McGraw-Hill, 1995: 1239-1277.
35. Naylor EW, Guthrie R. Newborn screening for maple syrup urine disease (branched-chain ketoaciduria). Pediatrics 1978; 61: 262-266.
36. Treacy E, Clow CL, Reade TR, et al. Maple syrup urine disease: interrelations between branched-chain amino-, oxo-and hydroxyacids; implications for treatment; associations with CNS dysmyelination. J Inherited Metab Dis 1992; 15: 121-135.
37. Chace DH, Hillman SL, Millington DS, et al. Rapid diagnosis of maple syrup urine disease in blood spots from newborns by tandem mass spectroscopy. Clin Chem 1995; 41: 62-68.
38. Mudd SH, Skovby F, Levy HL, et al. The natural history of homocystinuria due to cystathionine beta-synthase deficiency. Am J Human Genet 1985; 37: 1-31.
39. Mitchell GA, Lambert M, Tanguay RM. Hypertyrosinemia. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Bases of Inherited Disease, 7th edn. New York: McGraw-Hill, 1995: 1077-1106.
40. Hutchesson ACJ, Hall SK, Preece MA, Green A. Screening for tyrosinemia type 1. Arch Dis Child 1996; 74: F191-F194.
41. Whiteman PD, Clayton BE, Ersser RS, Lilly P, Seakins JW. Changing incidence of neonatal hypermethioninaemia: implications for the detection of homocystinuria. Arch Dis Child 1979; 54: 593-598.
42. Chace DH, Hillman SL, Millington DS, et al. Rapid diagnosis of homocystinuria and other hypermethionine-mias from newborns' blood spots by tandem mass spectroscopy. Clin Chem 1996; 42: 349-355.
43. Laberge C, Grenier A, Valet JP, Morissette J. Fumaryl-acetoacetase measurement as a mass-screening procedure for hereditary tyrosinemia type I. Am J Human Genet 1990; 47: 325-328.
44. Ziadeh R, Hoffman EP, Finegold DN, et al. Medium chain acyl-CoA dehydrogenase deficiency in Pennsylvania: neonatal screening shows high incidence and unexpected mutation frequencies. Pediatr Res 1995; 37: 675-678.
45. Chalmers RA. Disorders of organic acid metabolism. In: Holton JB, ed. The Inherited Metabolic Diseases. Edinburgh: Churchill Livingstone, 1994: 115-204.
46. Roe CR, Coates PM. Mitochondrial fatty acid oxidation
47. disorders. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Bases of Inherited Disease, 7th edn. New York: McGraw-Hill, 1995: 1501-1533.
48. Sweetman L, Williams JC. Branched Chain Organic Acidurias. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic And Molecular Bases of Inherited Disease, 7th edn. New York: McGraw-Hill, 1995: 1387-1422.
49. Fenton WA, Rosenberg LE. Disorders of propionate and methylmalonate metabolism. In: Scriver CS, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Bases of Inherited Disease, 7th ed. New York: McGraw-Hill, 1995: 1423-1449.
50. Wolf B. Worldwide survey of neonatal screening for biotinidase deficiency. J Inherited Metab Dis 1991; 14: 923-927.
51. Rudd BT. Prevalence of adrenal 21-hydroxylase deficiency in neonates born in the West Midlands: a retrospective study. J Inherited Metab Dis 1986; 9(Suppl 1): 155-156.
52. Wallace AM. Review of CAH screening programmes and the Scottish experience. J Inherited Metab Dis 1986; 9(Suppl 1): 135-141.
53. Pettit DA, Amador PS, Wolf B. The quantitation of biotinidase activity in dried blood spots using microtiter transfer plates: identification of biotinidase-deficient and heterozygous individuals. Analyt Biochem 1989; 179: 371-374.
54. Goldstein JL, Hobbs HH, Brown MS. Familial hypercholesterolemia. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Bases of Inherited Disease, 7th edn. New York: McGraw-Hill, 1995: 1981-2030.
55. Gillman MW. Screening for familial hypercholesterolemia in childhood. Am J Dis Child 1993; 147: 393-396.
56. Asami T. Screening for hypercholesterolaemia on blood spotted filterpaper. Lancet 1983; 2: 229-230.
57. Reilly M, Daly L, Hutchinson M. An epidemiological study of Wilson's disease in the Republic of Ireland. J Neurol Neurosurg Psychiat 1993; 56: 298-300.
58. Segal S. Galactosemia unsolved. Eur J Pediatr 1995; 154: S97-S102.
59. Brewer GJ, Dick RD, Yuzbasiyan-Gurkan V, Johnson V, Wang Y. Treatment of Wilson's disease with zinc. XIII: Therapy with zinc in presymptomatic patients from the time of diagnosis. J Lab Clin Med 1994; 123: 849-858.
60. Yarze JC, Martin P, Munoz SJ, Friedman LS. Wilson's disease: current status. Am J Med 1992; 92: 643-654.
61. Danks DM. Disorders of copper transport. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Bases of Inherited Disease, 7th edn. New York: McGraw-Hill, 1995: 2211-2235.
62. Schickling H, Schweitzer S, Shin Y, Diepenbrock F, Sander J. Neonatal screening for galactose metabolic defects. In: Farriaux J-P, Dhondt J-L, eds. New Horizons in Neonatal Screening. Amsterdam: Elsevier, 1994: 185-189.
63. Thibodeau DL, Andrews W, Meyer J, Mitchell P, Wolf B. Comparison of the effects of season and prematurity on the enzymatic newborn screening tests for galactosemia and biotipidase deficiency. Screening 1993; 2: 19-27.
64. Aoki T, Nakahashi M. New screening method for Wilson's disease and Menkes' kinky-hair disease. Lancet 1977; 2: 1140.
65. Fujioka Y, Aoki T, Shimizu N, et al. A new screening method for Wilson's disease by measuring blood caerulo-plasmin level. In: Farriaux J-P, Dhondt J-L, eds. New Horizons in Neonatal Screening. Amsterdam: Elsevier, 1994: 285-288.